Venus Remedies Share Price

Pharmaceuticals company Venus Remedies announced Q4FY26 & FY26 results Standalone Financial Highlights: Revenue from operations: For Q4FY26, the company reported revenue of Rs 259.01 crore, reflecting a QoQ increase of 43.94% (vs Q3FY26: Rs 179.95 crore) and a YoY increase of 31.65% (vs Q4FY25: Rs 196.74 crore). For FY26, the revenue from operations stood at Rs 768.73 crore, an annual growth of 19.28% compared to FY25 (Rs 644.47 crore). Total Income: Total income for Q4FY26 was Rs 263.64 crore, a QoQ growth of 44.57% (vs Q3FY26: Rs 182.36 crore) and a YoY growth of 31.29% (vs Q4FY25: Rs 200.81 crore). For FY26, the total income was Rs 780.19 crore, up 18.17% from FY25 (Rs 660.24 crore). Net Profit for the period: The profit for Q4FY26 was Rs 43.45 crore, reflecting a QoQ increase of 74.36% (vs Q3FY26: Rs 24.92 crore) and a YoY increase of 193.78% (vs Q4FY25: Rs 14.79 crore). For FY26, the net profit stood at Rs 99.31 crore, showing a growth of 89.00% compared to FY25 (Rs 52.55 crore). Earnings Per Share (EPS): The basic EPS for Q4FY26 was Rs 32.51, and For FY26, it was Rs 74.29. Consolidated Financial Highlights: Revenue from operations: For Q4FY26, the consolidated revenue was Rs 259.40 crore, an increase of 43.90% QoQ (vs Q3FY26: Rs 180.26 crore) and 31.24% YoY (vs Q4FY25: Rs 197.66 crore). For FY26, the consolidated revenue was Rs 769.60 crore, a growth of 17.88% compared to FY25 (Rs 652.89 crore). Total Income: Total consolidated income for Q4FY26 was Rs 264.35 crore, reflecting a QoQ increase of 44.63% (vs Q3FY26: Rs 182.78 crore) and a YoY increase of 31.04% (vs Q4FY25: Rs 201.73 crore). For FY26, the total income was Rs 782.18 crore, compared to Rs 668.84 crore in FY25, an increase of 16.95%. Net Profit (Attributable to Owners): The consolidated net profit attributable to the owners of the company for Q4FY26 was Rs 40.68 crore, compared to Rs 32.39 crore in Q3FY26 (a QoQ increase of 25.59%) and Rs 11.67 crore in Q4FY25 (a YoY increase of 248.59%). For FY26, the net profit attributable to owners was Rs 135.37 crore, an increase of 69.09% compared to FY25 (Rs 80.06 crore). Earnings Per Share (EPS): The basic EPS for Q4FY26 was Rs 35.53, and For FY26, it was Rs 76.89. Business Highlights: Segment Performance: The company operates in a single reportable segment, namely "Pharmaceuticals". Dividend: The Board has recommended a final dividend of Rs 10 per equity share (100% of face value of Rs 10 each) for FY26, subject to shareholder approval at the 37th Annual General Meeting. Subsidiaries: The company has a wholly-owned subsidiary, Venus Pharma GmbH in Germany, and a step-down subsidiary, Venus Pharma Kft in Hungary. Key Appointments: Mr. Saransh Chaudhary and Dr. Gurminder Singh Bedi were appointed as Additional Directors. Ms. Meenakshi Bishnoi was re-appointed as Chief Compliance Officer, and Mr. Kartik Chawda was appointed as Chief Information Officer & Head of IT, effective June 01, 2026. Result PDF

• Trendlyne
• 1 month ago

Plerixafor is a hematopoietic stem cell mobiliser used in combination with G-CSF to mobilise stem cells into peripheral blood for collection and autologous transplantation

• Business Line
• 1 month ago

Argentina is the fourth-largest pharmaceutical market in Latin America

• Business Line
• 1 month 2 weeks ago